Back to News
Market Impact: 0.25
Kazia Doses First Patient In Phase 2 PNOC035 Study Of Paxalisib In Pediatric Brain Cancer; Stock Up
Source: Nasdaq
Healthcare & BiotechProduct Launches
Kazia Therapeutics announced that the first patient has been dosed in Arm A of PNOC035, a Phase 2 platform study of lead oncology asset paxalisib combined with gemcitabine. The trial is evaluating the regimen in patients aged 1 to 39, marking a clinical-development milestone for paxalisib but providing no efficacy or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
KZIA0.55
More News
- Xencor reports phase 1 data for cancer drug XmAb819
- Biotech stocks are surging. How investors can play the new drug innovation boom
- UK immigration crackdown threatens £15 billion care sector
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Fact vs. fiction: Doctors share whether peptides are safe and effective
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More
- Alternative Data Due Diligence for Institutional Investors